Literature DB >> 16248999

Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin.

Margaret A Schwarz1, Hiahua Zheng, Jie Liu, Siobhan Corbett, Roderich E Schwarz.   

Abstract

Mature Endothelial-Monocyte Activating Polypeptide (mEMAP) II functions as a potent antiangiogenic peptide. Although the anti-tumor effect of mEMAP II has been described, little is known regarding its mechanism of action. Observations that mEMAP II induced apoptosis only in a subset of migrating and proliferating endothelial cells (EC) suggests a targeted effect on cells engaged in angiogenic activities which are known to rely upon cell adhesion and migration. Indeed, we demonstrate that mEMAP II inhibited fibronectin (FN) dependent microvascular EC (MEC) adhesion and spreading and we show that this depends upon the alpha5 beta1 integrin. Immunofluorescence analysis demonstrated that mEMAP II-dependent blockade of FN-alpha5 beta1 interactions was associated with disassembly of both actin stress fiber networks and FN matrix. These findings suggest that mEMAP II blocks MEC adhesion and spreading on fibronectin, via a direct interaction with the integrin alpha5 beta1, thus implicating that alpha5 integrin may be a mediator of mEMAP II's antiangiogenic function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248999     DOI: 10.1016/j.yexcr.2005.09.008

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Lung self-assembly is modulated by tissue surface tensions.

Authors:  Margaret A Schwarz; Haihua Zheng; Susan Legan; Ramsey A Foty
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-08       Impact factor: 6.914

2.  The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein.

Authors:  Haiming Xu; Nikolay L Malinin; Niranjan Awasthi; Roderich E Schwarz; Margaret A Schwarz
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

3.  Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.

Authors:  Mijung Kwon; Engy Hanna; Dominique Lorang; Mei He; John S Quick; Asha Adem; Christina Stevenson; Joon-Yong Chung; Stephen M Hewitt; Enrique Zudaire; Dominic Esposito; Frank Cuttitta; Steven K Libutti
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 4.  Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II).

Authors:  Charitharth Vivek Lal; Margaret A Schwarz
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03-12

5.  Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation.

Authors:  Yao Chen; Susan K Legan; Anne Mahan; Janet Thornton; Haiming Xu; Margaret A Schwarz
Journal:  Respir Res       Date:  2012-01-03

6.  Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.

Authors:  Margaret A Schwarz; Janet Thornton; Haiming Xu; Niranjan Awasthi; Roderich E Schwarz
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

7.  Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Winston Ruan; Margaret A Schwarz; Roderich E Schwarz
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

Review 8.  Regulation of angiogenesis by aminoacyl-tRNA synthetases.

Authors:  Adam C Mirando; Christopher S Francklyn; Karen M Lounsbury
Journal:  Int J Mol Sci       Date:  2014-12-19       Impact factor: 5.923

9.  Combination of Endothelial-Monocyte-Activating Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR Signal Pathway.

Authors:  Wei Zhou; Libo Liu; Yixue Xue; Jian Zheng; Xiaobai Liu; Jun Ma; Zhen Li; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2017-03-13       Impact factor: 5.639

10.  Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Authors:  Niranjan Awasthi; Changhua Zhang; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  J Exp Clin Cancer Res       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.